Subject(s)
Compassionate Use Trials/legislation & jurisprudence , Anthracyclines/adverse effects , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/economics , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Bevacizumab , Cardiomyopathies/chemically induced , Cardiomyopathies/drug therapy , Compassionate Use Trials/economics , Drug Costs , Humans , Macular Degeneration/drug therapy , Ranibizumab , Razoxane/administration & dosage , Razoxane/economics , Razoxane/therapeutic use , SpainABSTRACT
No disponible
No disponible
Subject(s)
Humans , Female , Aged , Monoamine Oxidase Inhibitors/adverse effects , Serotonin Syndrome/chemically induced , Serotonin Syndrome/diagnosisSubject(s)
Drug Interactions , Herb-Drug Interactions , Phytotherapy , Algorithms , Humans , Probability , Risk FactorsABSTRACT
No disponible
Subject(s)
Humans , Drug Interactions , Food-Drug Interactions , Herb-Drug Interactions , Predictive Value of TestsABSTRACT
No disponible
Subject(s)
Humans , Internet , Drug Prescriptions/statistics & numerical data , Drug Information Services , Quality of Health Care , Quality ControlABSTRACT
Mental disorders mortality rates are low but they are extremely disabling so that the diagnosis and treatment of mental illness is an important task for public health and it is central in current therapy strategies and sanitary policy. The aim of this study is to analyse conditions influencing antidepressants and antipsychotics use in Spain from 1997 to 2004. Tryciclic antidepressants have been of first-choice in depression treatment for many years but their side effects profile are related to a lack of treatment adherence. Trying to increase tolerance, new antidepressants have been developed and research into new therapeutic uses is being done. These are some of the reasons causing an increase in medical utilization and costs. Medical boxes sold have increased from 14,14 million in 1997 to 26,76 million in 2004, meaning 168,61 and 447,11 million euros respectively. Antipsychotic use has been maintained, 11,74 million boxes in 1997 and 12,65 in 2004; however, there has been a rise in price from 61,84 to 317,46 million euros due to second generation antipsychotics prescription (mainly risperidone and olanzapine) Some conditions have contributed to current situation: increased number of diagnosed patients with depression and other mental disorders, new approved therapeutic uses and a rise in elderly people receiving new antipsychotic agents. Moreover, promotional marketing is causing an increase in new recently commercialised drugs use.
Subject(s)
Antidepressive Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Mental Disorders/drug therapy , Pharmaceutical Services/statistics & numerical data , Aged , Alzheimer Disease/drug therapy , Alzheimer Disease/epidemiology , Antidepressive Agents/adverse effects , Antidepressive Agents/economics , Antipsychotic Agents/adverse effects , Antipsychotic Agents/economics , Clinical Trials as Topic , Depressive Disorder/drug therapy , Depressive Disorder/epidemiology , Drug Costs/statistics & numerical data , Drug Design , Drug Utilization/economics , Drug Utilization/statistics & numerical data , Drug Utilization/trends , Economics, Pharmaceutical/trends , Humans , Marketing of Health Services/trends , Mental Disorders/epidemiology , National Health Programs/economics , National Health Programs/statistics & numerical data , Pharmaceutical Services/economics , Pharmaceutical Services/trends , Practice Patterns, Physicians'/economics , Practice Patterns, Physicians'/statistics & numerical data , Practice Patterns, Physicians'/trends , Prescription Fees/statistics & numerical data , Schizophrenia/drug therapy , Schizophrenia/epidemiology , Spain/epidemiologyABSTRACT
Las enfermedades mentales presentan una baja mortalidad pero son altamente discapacitantes, lo que ha hecho que su diagnóstico y tratamiento ocupen un papel cada vez más relevante en la terapia actual y en las políticas sanitarias. En este escenario se planteó este estudio, que pretende analizar los factores que pueden haber influido en la utilización de antidepresivos y antipsicóticos en España durante el período 1997-2004. Los antidepresivos tricíclicos son los fármacos de referencia para tratar la depresión, pero a su perfil de efectos adversos se ha atribuido una falta de adherencia. La búsqueda de una mejor tolerancia, en un mercado en auge, ha favorecido la síntesis de nuevos antidepresivos y la investigación de nuevas indicaciones. Esto explicaría en buena parte el crecimiento del consumo de este grupo, tanto en unidades como en ventas, que ha pasado de 14,14 a 26,79 millones de envases y de 168,61 a 447,11 millones de euros en valor. En el caso de los antipsicóticos su utilización se ha mantenido más o menos estable, pasando de 11,74 a 12,65 millones de envases, pero el aumento de facturación ha sido espectacular: ha pasado de 61,84 a 317,46 millones de euros; la risperidona y la olanzapina son las principales causantes de este incremento. Muchos pacientes tratados con antipsicóticos de primera generación han pasado a ser tratados con estos nuevos antipsicóticos. Algunos factores que han contribuido a la situación actual son el mayor número de depresiones diagnosticadas, así como de otras enfermedades mentales, el aumento del número de indicaciones aprobadas y el crecimiento de la población anciana tratada con los nuevos antipsicóticos. Todo ello, junto con el marketing promocional, ha disparado la utilización de los principios activos de más reciente comercialización (AU)
Mental disorders mortality rates are low but they are extremely disabling so that the diagnosis and treatment of mental illness is an important task for public health and it is central in current therapy strategies and sanitary policy. The aim of this study is to analyse conditions influencing antidepressants and antipsychotics use in Spain from 1997 to 2004. Tryciclic antidepressants have been of first-choice in depression treatment for many years but their side effects profile are related to a lack of treatment adherence. Trying to increase tolerance, new antidepressants have been developed and research into new therapeutic uses is being done. These are some of the reasons causing an increase in medical utilization and costs. Medical boxes sold have increased from 14,14 million in 1997 to 26,76 million in 2004, meaning 168,61 and 447,11 million euros respectively. Antipsychotic use has been maintained, 11,74 million boxes in 1997 and 12,65 in 2004; however, there has been a rise in price from 61,84 to 317,46 million euros due to second generation antipsychotics prescription (mainly risperidone and olanzapine). Some conditions have contributed to current situation: increased number of diagnosed patients with depression and other mental disorders, new approved therapeutic uses and a rise in elderly people receiving new antipsychotic agents. Moreover, promotional marketing is causing an increase in new recently commercialised drugs use (AU)
